SCTX (Scribe Therapeutics) OCF Margin %: -338.33% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics OCF Margin %?

Scribe Therapeutics SCTX -13.40% 8 OCF Margin % is -338.33% as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Scribe Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-7.56 Mil. Scribe Therapeutics's Revenue for the three months ended in Mar. 2026 was $2.23 Mil. Therefore, Scribe Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was -338.33%.

As of today, Scribe Therapeutics's current OCF Yield % is -320,800.00%.

The historical rank and industry rank for Scribe Therapeutics's OCF Margin % or its related term are showing as below:


SCTX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Scribe Therapeutics OCF Margin % Related Terms

Scribe Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics OCF Margin % Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
OCF Margin %
-165.01 -88.35

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
OCF Margin % 0.00 -79.54 0.00 -338.33
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Scribe Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-45.213/51.174
=-88.35 %

Scribe Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.555/2.233
=-338.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -338.33% mean?
Scribe Therapeutics (SCTX) has a OCF Margin % of -338.33% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' OCF Margin % too high?
Scribe Therapeutics' current OCF Margin % is -338.33%. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' OCF Margin % compare to ?
Scribe Therapeutics' OCF Margin % of -338.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current OCF Margin % is -338.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current OCF Margin % of -338.33%. The current OCF Margin % is -338.33%. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current OCF Margin % is -338.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price